Prognostic Value of Pretreatment Glasgow Prognostic Score/Modified Glasgow Prognostic Score in Ovarian Cancer: A Systematic Review and Meta-Analysis

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.21387
   PubMed Web of Science ®Google Scholar
• Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351(24):2519–2529. doi:10.1056/NEJMra041842
   PubMed Web of Science ®Google Scholar
• Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, Grant P, Rice GE. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol. 2010;136(7):1079–1088. doi:10.1007/s00432-009-0755-5
   PubMed Web of Science ®Google Scholar
• Huang Y, Ming X, Li B, Li Z. Histological characteristics and early-stage diagnosis are associated with better survival in young patients with epithelial ovarian cancer: a retrospective analysis based on surveillance epidemiology and end results database. Front Oncol. 2020;10:595789. doi:10.3389/fonc.2020.595789
   PubMed Web of Science ®Google Scholar
• Liang W-F, Wang L-J, Li H, Liu C-H, Wu M-F, Li J. The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease. J Cancer. 2021;12(3):946–953. doi:10.7150/jca.52711
   PubMed Web of Science ®Google Scholar
• Li J, Wang Y, Wu Y, Li J, Che G. Prognostic value of pretreatment albumin to globulin ratio in lung cancer: a meta-analysis. Nutr Cancer. 2020. 2021;73(1):75–82. doi:10.1080/0163558117155
   Google Scholar
• Wang Y, Che G. Prognostic value of biomarkers in primary small cell carcinoma of the esophagus. Thorac Cancer. 2020;11(5):1119–1120. doi:10.1111/1759-7714.13369
   PubMed Web of Science ®Google Scholar
• Wang Y, Lin L, Ji Y, Mei X, Zhao C, Chen Y, Che G. Prognostic value of the advanced lung cancer inflammation index in early-stage non-small cell lung cancer patients undergoing video-assisted thoracoscopic pulmonary resection. Ann Palliat Med. 2020;9(4):425–729. doi:10.21037/apm.2020.03.18
   Web of Science ®Google Scholar
• Wang Y, Hu X, Huang Y, Xu W-Y, Wu Y-M, Li P-F, Che G-W. Prognostic value of the C-reactive protein to albumin ratio in esophageal cancer: a systematic review and meta-analysis. Kaohsiung J Med Sci. 2020;36(1):54–61. doi:10.1002/kjm2.12129
   PubMed Web of Science ®Google Scholar
• Wang Y, Li S, Hu X, Wang Y, Wu Y, Li P, Che G. The prognostic value of serum albumin-globulin ratio in early-stage non-small cell lung cancer: a retrospective study. CMAR. 2019;11:3545–3554. doi:10.2147/CMAR.S191288
   Web of Science ®Google Scholar
• Wang Y, Li Y, Chen P, Xu W, Wu Y, Che G. Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis. Ann Transl Med. 2019;7(18):433–433. doi:10.21037/atm.2019.08.116
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang D, Xu W-Y, Wang Y-W, Che G-W. Prognostic value of pretreatment lymphocyte-to-monocyte ratio in non-small cell lung cancer: a meta-analysis. Oncol Res Treat. 2019;42(10):523–530. doi:10.1159/000501726
   PubMed Web of Science ®Google Scholar
• Dong M, Shi Y, Yang J, Zhou Q, Lian Y, Wang D, Ma T, Zhang Y, Mi Y, Gu X, et al. Prognostic and clinicopathological significance of systemic immune-inflammation index in colorectal cancer: a meta-analysis. Ther Adv Med Oncol. 2020;12:1–14. doi:10.1177/1758835920937425
   Web of Science ®Google Scholar
• Huang Y, Gao Y, Wu Y, Lin H. Prognostic value of systemic immune-inflammation index in patients with urologic cancers: a meta-analysis. Cancer Cell Int. 2020;20:499. doi:10.1186/s12935-020-01590-4
   PubMed Web of Science ®Google Scholar
• Ji Y, Wang H. Prognostic prediction of systemic immune-inflammation index for patients with gynecological and breast cancers: a meta-analysis. World J Surg Onc. 2020;18(1):197. doi:10.1186/s12957-020-01974-w
   PubMed Web of Science ®Google Scholar
• Marnell L, Mold C, Du Clos TW. Du Clos TW: C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol. 2005;117(2):104–111. doi:10.1016/j.clim.2005.08.004
   PubMed Web of Science ®Google Scholar
• Nie D, Zhang L, Wang C, Guo Q, Mao X. A high Glasgow prognostic score (GPS) or modified Glasgow prognostic score (mGPS) predicts poor prognosis in gynecologic cancers: a systematic review and meta-analysis. Arch Gynecol Obstet. 2020;301(6):1543–1551. doi:10.1007/s00404-020-05581-8
   PubMed Web of Science ®Google Scholar
• Wang Y, Chen L, Wu Y, Li P, Che G. The prognostic value of modified Glasgow prognostic score in patients with esophageal squamous cell cancer: a Meta-analysis. Nutr Cancer. 2020;72(7):1146–1154. doi:10.1080/01635581.2019.1677925
   PubMed Web of Science ®Google Scholar
• Wu D, Wang X, Shi G, Sun H, Ge G. Prognostic and clinical significance of modified Glasgow prognostic score in pancreatic cancer: a meta-analysis of 4,629 patients. Aging. 2021;13(1):1410–1421. doi:10.18632/aging.202357
   PubMedGoogle Scholar
• Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Rev Esp Nutr Hum Diet. 2016;20:148–160. doi:10.14306/renhyd.20.2.223
   Google Scholar
• Wang Y, Li P, Li J, Lai Y, Zhou K, Wang X, Che G. The prognostic value of pretreatment Glasgow prognostic score in patients with esophageal cancer: a meta-analysis. CMAR. 2019;11:8181–8190. doi:10.2147/CMAR.S203425
   Web of Science ®Google Scholar
• Wang Y, Chen L, Wu Y, Li P, Che G. The prognostic value of modified Glasgow prognostic score in patients with esophageal squamous cell cancer: a Meta-analysis. Nutr Cancer. 2020;72(7):1146–1154. doi:10.1080/01635581.2019.1677925
   PubMed Web of Science ®Google Scholar
• Chang H, Holzapfel M, Walsh C, Li AJ. The inflammation-based Glasgow prognostic score predicts poor survival in advanced stage epithelial ovarian cancer. Gynecol Oncol. 2015;139(1):192. doi:10.1016/j.ygyno.2015.07.055
   Web of Science ®Google Scholar
• Liang M, Holzapfel M, Chang H, Lester J, Li A, Cass I, Rimel BJ, Karlan B, Leuchter R, Walsh C, et al. Glasgow prognostic score associated with lower rates of R0 cytoreduction in women with stage III serous ovarian cancer. Gynecol Oncol. 2016;143(1):219. doi:10.1016/j.ygyno.2016.08.304
   Web of Science ®Google Scholar
• Liu Y, Chen S, Zheng C, Ding M, Zhang L, Wang L, Xie M, Zhou J. The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. BMC Cancer. 2017;17(1). doi:10.1186/s12885-017-3220-x
   Web of Science ®Google Scholar
• Omichi C, Nakamura K, Haraga J, Masuyama H, Hiramatsu Y. Glasgow prognostic score is an independent marker for poor prognosis with all cases of epithelial ovarian cancer. Cancer Med. 2016;5(6):1074–1080. doi:10.1002/cam4.681
   PubMed Web of Science ®Google Scholar
• Roncolato FT, Berton-Rigaud D, O’Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, et al. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS). Gynecol Oncol. 2018;148(1):36–41. doi:10.1016/j.ygyno.2017.10.019
   PubMed Web of Science ®Google Scholar
• Sharma R, Hook J, Kumar M, Gabra H. Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer. 2008;44(2):251–256. doi:10.1016/j.ejca.2007.11.011
   PubMed Web of Science ®Google Scholar
• Zhang W, Ye B, Liang W, Ren Y. Preoperative prognostic nutritional index is a powerful predictor of prognosis in patients with stage III ovarian cancer. Sci Rep. 2017;7(1):9548. doi:10.1038/s41598-017-10328-8
   PubMed Web of Science ®Google Scholar
• Zhu J, Wang H, Liu C-C, Lu Y, Tang H. The Glasgow prognostic score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study. J Cancer Res Clin Oncol. 2016;142(11):2339–2345. doi:10.1007/s00432-016-2228-y
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):E493–E503. doi:10.1016/S1470-2045(14)70263-3
   PubMed Web of Science ®Google Scholar
• Salas-Benito D, Vercher E, Conde E, Glez-Vaz J, Tamayo I, Hervas-Stubbs S. Inflammation and immunity in ovarian cancer. EJC Suppl. 2020;15:56–66. doi:10.1016/j.ejcsup.2019.12.002
   PubMedGoogle Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G, Knox JF, Tran B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106:dju124. doi:10.1093/jnci/dju124
   PubMedGoogle Scholar
• Sahin HO, Aydin Z, Toktas IU, Toraman C, Yuksel IT, Seyhan A, Akbayir O. Clinical and prognostic value of pre-operative systemic inflammatory markers in clinical course and prognosis of ovarian cancer. Eur J Gynaecol Oncol. 2020;41:924–930. doi:10.31083/j.ejgo.2020.06.2118
   Web of Science ®Google Scholar
• Castell JV, Gómez-Lechón MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990;12(5):1179–1186. doi:10.1002/hep.1840120517
   PubMed Web of Science ®Google Scholar
• Moses AGW, Maingay J, Sangster K, Fearon KCH, Ross JA. Pro-inflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol Rep. 2009;21(4):1091–1095. doi:10.3892/or_00000328
   PubMed Web of Science ®Google Scholar
• Zhang H, Ren D, Jin X, Wu H. The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis. Cancer Cell Int. 2020;20:462. doi:10.1186/s12935-020-01558-4
   PubMed Web of Science ®Google Scholar
• Arroyo V, Garcia-Martinez R, Salvatella X. Human serum albumin, systemic inflammation, and cirrhosis. J Hepatol. 2014;61(2):396–407. doi:10.1016/j.jhep.2014.04.012
   PubMed Web of Science ®Google Scholar
• Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69. doi: 10.1186/1475-2891-9.
   PubMed Web of Science ®Google Scholar
• Pang K, Chen B, Han C. Prognostic value of modified Glasgow prognostic score in bladder cancer: a systematic review and meta-analysis. Int J Urol. 2020;27:48–49.
   Web of Science ®Google Scholar
• Tong T, Guan Y, Xiong H, Wang L, Pang J. A meta-analysis of Glasgow prognostic score and modified Glasgow prognostic score as biomarkers for predicting survival outcome in renal cell carcinoma. Front Oncol. 2020;10:1541. doi: 10.3389/fonc.2020.0.
   PubMed Web of Science ®Google Scholar